Clinical Trial Update: Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A [Phase 4]

View source ↗

Summary

A Phase 4 pharmacokinetic study of ADVATE (antihemophilic factor VIII) 3000 IU in previously treated patients with severe Hemophilia A has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ADVATE (antihemophilic factor VIII)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia A | Phase 4 | Status: COMPLETED | Results posted: 2013-09-05